CK Life Sciences Int'l., (Holdings) Inc.
長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 0775)

INSIDE INFORMATION - PROMISING EARLY RESULTS OF NOVEL CANCER VACCINES TARGETING TROP2 (TROPHOBLAST CELL SURFACE ANTIGEN 2) AND RESUMPTION OF TRADING

CK Life Sciences Int'l., (Holdings) Inc. (the **"Company"**) announces that it has obtained promising early results in laboratory tests of its preclinical stage novel cancer vaccines targeting Trophoblast Cell Surface Antigen 2 (**"TROP2"**).

TROP2 is a cell surface glycoprotein that is overexpressed in a wide range of cancers, including breast, lung, pancreatic, and colorectal cancers. This protein plays a critical role in cell proliferation, migration, and invasion, and its overexpression is frequently linked to aggressive tumor behavior and poor clinical outcomes. Given its high expression in cancer cells and minimal presence in normal tissues, TROP2 has emerged as a promising therapeutic target in oncology.

The Company's TROP2 cancer vaccine candidates include innovative circular mRNA ("**circRNA**") and fusion protein vaccine constructs that can induce robust T cell immune responses and have demonstrated impressive tumor growth inhibition in preclinical studies. These TROP2 vaccine candidates have been evaluated in five preclinical studies across two tumor types — breast cancer and colorectal cancer — involving over 170 mice, with approximately 100 mice administered a TROP2 vaccine candidate. All breast cancer studies showed complete (100%) tumor growth inhibition. Overall, 100% inhibition of tumor growth was achieved in four of the five studies when mice were treated with a TROP2 vaccine candidate, while the remaining study demonstrated approximately 80% tumor growth inhibition.

Breast cancer rates in Asia are rising sharply, with younger women disproportionately affected. Of particular concern is triple-negative breast cancer (TNBC), which shows both higher prevalence and more aggressive behavior in Asian populations compared to Western counterparts. Defined by its lack of estrogen, progesterone, and HER2 receptors, TNBC has fewer treatment options and demonstrates significantly higher rates of metastasis and recurrence than other breast cancer subtypes.

The Company considers that TROP2 is an exciting therapeutic target, and the anti-cancer efficacy observed in mouse studies of the Company's TROP2 cancer vaccines is unprecedented. The Company looks forward to progressing a TROP2 cancer vaccine expeditiously into clinical trials to benefit patients. Prior to this announcement, the Company has filed an Original Grant Patent application with the Intellectual Property Department of Hong Kong and a provisional patent application with the U.S. Patent and Trademark Office for its circRNA and fusion protein TROP2 cancer vaccines.

After a thorough assessment, the Company concluded that the successful commercialisation of this TROP2 cancer vaccine could potentially generate significant economic benefits for the Company.

Data on the TROP2 cancer vaccines will be presented at upcoming cancer conferences. In recent years, the Company has showcased its growing early-stage cancer vaccine pipeline through preclinical data presentations at leading oncology conferences, alongside the filing of multiple patents. Developed in its Hong Kong-based R&D laboratories, these innovative vaccines target a broad spectrum of tumor antigens, immune checkpoint proteins, and other key components within the tumor-immune microenvironment.

An application has been made by the Company to the Stock Exchange for the resumption of trading in the Company's shares with effect from 9:00 a.m. on 11 April 2025.

It should be noted that the research is only at a preclinical stage and the Company has not yet commenced clinical trials for TROP2 cancer vaccines and accordingly, there is no assurance of the outcome. There is also no assurance that the patents for the TROP2 cancer vaccines will be granted. Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 11 April 2025

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Mr. Lance Richard Lee Yuen and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).